Key Points
- CFO Oluyemi Okupe sold 29,277 Hims & Hers shares for approximately $876,846 under a pre-arranged Rule 10b5-1 trading plan, reducing his ownership by 11.01% to 236,527 shares.
- Hims & Hers reported strong revenue growth of 38.2% year over year to $753.2 million, but its $0.37 quarterly EPS loss significantly missed the $0.05 expected loss, highlighting ongoing profitability concerns.
- Analysts maintain a consensus “Hold” rating with an average price target of $32.43, while legal and regulatory risks, negative cash flow, and high stock volatility remain important potential pressures.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 29,277 shares of the firm's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15. Following the sale, the chief financial officer directly owned 236,527 shares of the company's stock, valued at approximately $7,083,983.65. The trade was a 11.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.82, for a total transaction of $354,860.66.
- On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.99, for a total transaction of $148,090.62.
- On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total transaction of $261,831.32.
- On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total value of $261,377.87.
Hims & Hers Health Stock Down 6.6%
Shares of NYSE HIMS opened at $28.43 on Thursday. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $65.30. The stock's 50-day simple moving average is $29.69 and its 200-day simple moving average is $27.97. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of -45.13 and a beta of 2.42.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million during the quarter, compared to analysts' expectations of $698.90 million. During the same period in the prior year, the company posted $0.17 EPS. The company's revenue for the quarter was up 38.2% on a year-over-year basis. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
HIMS has been the subject of a number of recent analyst reports. TD Cowen raised their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. assumed coverage on shares of Hims & Hers Health in a report on Friday, September 11th. They issued a "neutral" rating and a $32.00 price target on the stock. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Truist Financial raised their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a report on Monday, August 24th. Finally, Bank of America boosted their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and an average price target of $32.43.
Get Our Latest Analysis on Hims & Hers Health
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after purchasing an additional 319 shares in the last quarter. Sigma Planning Corp boosted its holdings in Hims & Hers Health by 1.5% during the first quarter. Sigma Planning Corp now owns 26,007 shares of the company's stock worth $540,000 after buying an additional 388 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after buying an additional 665 shares in the last quarter. BIP Wealth LLC grew its position in Hims & Hers Health by 6.0% in the first quarter. BIP Wealth LLC now owns 16,278 shares of the company's stock worth $338,000 after buying an additional 915 shares during the last quarter. Finally, Winnow Wealth LLC grew its position in Hims & Hers Health by 4.6% in the fourth quarter. Winnow Wealth LLC now owns 22,282 shares of the company's stock worth $735,000 after buying an additional 980 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.
Key Stories Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Hims & Hers continues to show strong operating growth. Second-quarter revenue increased 38.2% year over year to $753.2 million, exceeding estimates, while the company added approximately 300,000 subscribers and raised full-year 2026 revenue guidance to $3.1 billion-$3.3 billion. Management also cited early benefits from its AI care platform, including lower support costs and cancellation rates. Hims & Hers revenue and profitability article
- Neutral Sentiment: CFO Oluyemi Okupe sold 29,277 shares worth approximately $876,846 under a pre-arranged Rule 10b5-1 trading plan. Although insider selling can weigh on sentiment, the planned nature of the transaction reduces its significance; Okupe continued to own 236,527 shares afterward. SEC insider transaction filing
- Negative Sentiment: The key pressure is legal and regulatory exposure. The FTC alleges that Hims & Hers shared sensitive health information with advertising platforms and used unclear subscription cancellation and prescription-billing practices. A shareholder class action alleges that executives made materially misleading statements and failed to disclose risks; investors have until November 2, 2026, to seek lead-plaintiff status. The litigation could increase legal expenses and further damage the company’s reputation. Hims & Hers securities class action article
- Negative Sentiment: Profitability remains a concern. Second-quarter EPS was a loss of $0.37 versus an expected loss of $0.05, free cash flow was negative $68 million, and approximately $81 million of acquisition, restructuring, and FTC-related costs were recorded. Additional litigation costs may pressure future results, while the stock’s high volatility and substantial short interest amplify downside risk.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.
Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.
The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
